*Any dose means standard name-brand dose options through 15 mg, subject to licensed-provider review
Comparative Market Position: Novo Nordisk's Wegovy (semaglutide): Wegovy is Zepbound's primary direct competitor, also a GLP-1 receptor agonist approved for chronic weight management
108: 86180 Dyck PJ, Karnes JL, OBrien PC, et al
Who is eligible for compounded tirzepatide
Promotional superlatives and headline marketing phrases appearing on the brand's website - including, without limitation, "Physician-Guided," "No Hidden Fees," "Doctor-led Plans & Coaching," and "Quality is our guarantee" - are explicitly identified in this article (including in the dedicated "About the Promotional Language" and "How to Read RxSpan MD's Marketing Language" sections) as brand-asserted marketing language and are not represented as independent third-party rankings, performance guarantees, or laboratory-verified claims by this publication
Backert et al., 2015)
